NewAmsterdam Pharma Company N.V.
NAMS
$36.47
-$3.98-9.84%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -17.36M | -39.53M | -92.18M | -16.65M | -39.01M |
| Total Depreciation and Amortization | 45.00K | 52.00K | 51.00K | 28.00K | 19.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.49M | -7.34M | 62.63M | 4.09M | -406.00K |
| Change in Net Operating Assets | -23.84M | 10.35M | -7.98M | 28.00K | -14.59M |
| Cash from Operations | -37.67M | -36.47M | -37.48M | -12.50M | -53.98M |
| Capital Expenditure | -88.00K | -16.00K | -3.00K | -75.00K | -209.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -159.05M | 2.87M | -62.18M | -- | -- |
| Cash from Investing | -159.14M | 2.86M | -62.18M | -75.00K | -209.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3.43M | 8.11M | 456.64M | 58.00K | 4.66M |
| Repurchase of Common Stock | -- | -- | 0.00 | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00 | -1.59M | -25.00K | 0.00 | 0.00 |
| Cash from Financing | 3.43M | 6.52M | 456.61M | 58.00K | 4.66M |
| Foreign Exchange rate Adjustments | 8.83M | 3.77M | -7.94M | 4.54M | -909.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -184.56M | -23.32M | 349.01M | -7.98M | -50.44M |